HER2 as a predictor of response to dual HER2 blockade without cytotoxic treatment

摘要

The present invention provides for the detection and / or detection of HER2 expression in an isolated biological sample of a patient, either before (1) or before (2) prior to anti-HER2 treatment without chemotherapy treatment. Or in vitro methods for determining the efficacy of anti-HER2 treatment without chemotherapy in patients with HER2-positive breast cancer, including quantification. The present invention provides an in vitro marker for determining the efficacy of anti-HER2 treatment without chemotherapy in patients with HER2-positive breast cancer, or alternatively, the use of anti-HER2 treatment without chemotherapy in patients with HER2-positive breast cancer. It also relates to the use of the HER2 gene expression product as an in vitro marker to determine or recommend whether to initiate an alternative medical regimen.